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CDAN2ic anemias (CDA) were classiﬁed according to bone marrow changes and
biochemical features 40 years ago. A consistent ﬁnding in CDA type II, the most frequent subgroup of CDAs
is a relevant hypoglycosylation of erythrocyte membrane proteins. It is a matter of debate if the
hypoglycosylation is the primary cause of the disorder or a phenomenon secondary to other
pathomechanisms. The molecular cause of the disorder is still unknown although some enzyme
deﬁciencies have been proposed to cause CDA II in the last 2 decades and a linkage analysis locating
the CDA II gene in a 5 cM region on chromosome 20 was done in 1997. In this review biochemical and
genetic data are discussed and diagnostic methods based on biochemical observations of the recent years
are reviewed.
© 2009 Elsevier B.V. All rights reserved.1. The family of congenital dyserythropoietic anemiasCongenital dyserythropoietic anemia type II (CDA II) also known as
hereditary erythroblastic multinuclearity with positive acidiﬁed-
serum test (HEMPAS) is the most frequent member of the family of
congenital dyserythropoietic anemias consisting of three entities:
CDA I is characterized by megaloblastic changes, ineffective
erythropoiesis and nuclear abnormalities of erythroblasts including
a “Swiss cheese”—aspect of erythroblasts on electron microscopy.
Hemoglobin levels are variablewithmean hemoglobin levels between
8–11 mg/dl [1]. The disorder follows an autosomal recessive trait.
After linkage analysis [2] the gene defect in CDA I could be
characterized as codanin-1 (CDAN1) [3]; the function of the gene
product is unknown. In about 10% of CDA I patients skeletal
abnormalities are associated with the disorder [4]. Several patients
show a response to alpha-interferon therapy with increased blood-D-mannoside β-1,2-N-acetyl-
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ll rights reserved.hemoglobin levels and decreased iron overload. More than 150
patients suffering from CDA I are known.
CDA III is a more heterogeneous disorder consisting of subtypes
with an autosomal recessive trait or sporadic occurrence. Most data
are derived from a large family living in Sweden. Patients show
dyserythropoiesis with giant multinucleated erythroblasts. In most
cases anemia is mild and does not require transfusions. In contrast to
other types of CDA no relevant iron overload can be noticed.
Only a few patients with CDA III have been described. The genetic
defect is unknown although mapping analysis located the CDA III-
gene to a 4.5 cM interval at chromosome 15p23 [5].
CDA II is the most frequent member of the congenital dysery-
thropoietic anemia family. More than 300 patients are known [6]. CDA
II patients show characteristic biochemical and bone marrow changes
that can be used for diagnostic purposes. A common ﬁnding in all
typical CDA II patients is an impaired glycosylation of erythrocyte
membrane proteins [7]. The molecular basis is still unknown.
2. Clinical picture of CDA II
Mild to severe anemia, jaundice and splenomegaly are the
predominant symptoms. Red cell size is mostly normocytic; the
mean hemoglobin concentration is 9.1–9.8 g/dl [6]. Most CDA II
patients do not require regular transfusions. However, up to 15% of the
patients show transfusion dependent anemia and some patients were
treated by bone marrow transplantation [8]. The mean age at
diagnosis in a large collection of patients was 18.2 years [6].
Splenomegaly is present in 50–60% of CDA II patients. Beyond the
age of 20 most patients develop iron overload and some patients
develop liver cirrhosis, diabetes and heart failure [6,9].
Fig. 2. Oligosaccharides of Band 3. Crucial Golgi enzymes for the assembly of normal
polylactosamines in the Golgi. Assembly of the precursor oligosaccharide shown on the
left is carried out in the endoplasmic reticulum. This glycan is transported to the Golgi
apparatus for further processing to the glycan shown on the right. Three Man residues
are cleaved by αManI (1), ′a GlcNAc is attached to the Man-α-1,3 branch by GnTI (2),
two Man residues on the Man α1,6 branch are cleaved by α-ManII (3), and a second
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The classiﬁcation of congenital dyserythropoietic anemias was
done on the basis of characteristic changes of bone marrow cytology
[10]. Bone marrow samples show distinct hypercellularity due to
erythroid hyperplasia with 45–90% erythroid precursors. In CDA II, 10
to 45 percent (mean 20%) of all erythroblasts are bi- and multi-
nucleated [10,11] (Fig. 1). If characteristic erythroblasts are present the
diagnosis of CDA II is very likely although cases with typical bone
marrow morphology but without typical biochemical alterations are
known.
4. Biochemical changes in CDA II
4.1. Glycosylation in CDA II
CDA II Band 3 (anion exchange protein 1) and band 4.5 (glucose
transporter 1), two abundant erythrocyte membrane proteins, show a
sharper band and faster migration on sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) due to decreased
glycosylation [12,13]. The main erythrocyte membrane protein
represents band 3 comprising 25–30% of total erythrocyte membrane
protein [14]. Band 3 normally carries two polylactosamine chains ([-
3Galβ1,4-GlcNAcβ1-]n) attached to a single N-linked bi-antennary
asparagine-linked trimannosyl core structure [15] (Fig. 2). In CDA II,
band 3 and other red blood cell membrane proteins carry altered N-
glycans with truncated polylactosamine structures [15,16]. ImmatureFig. 1. Characteristic changes in red blood cells and bone marrow in HEMPAS. (A) bone
marrow smear showing bi- and multinuclear erythroblasts and hypercellularity. (B)
Double membrane of erythrocytes due to residual endoplasmic reticulum. (C)
Erythrocyte ghost extracts analysed by SDS-PAGE show that CDA II band 3 is sharper
than control band 3 due to truncated N-glycans. (D) A tomato lectin blot of the same gel
as in (C) shows that the lectin does not bind to erythrocyte glycoproteins in CDA II
patients.
GlcNAc is attached to the Man α1,6 branch by GnT-II (4). In some glycans, FuT8 now
attaches a fucose in α 1,6 linkage to the core GlcNAc (5). Elongation of the
oligosaccharide is performed in the trans-Golgi probably by several β1,4-galactosyl-
transferases (6) and i-GnT (7) resulting in linear polylactosamines with variable length
(i-antigen). Branching of linear polylactosamines by adding a GlcNAc in β1,6-linkage to
galactose of the linear polylactosamines (I-GnT, 8) and further elongation of this GlcNAc
by β1,4-galactosyltransferases (6) leads to the expression of the I-antigen. Sialic acid
and oligosaccharides determining blood group characteristics are usually attached to
terminal galactose of band 3 polylactosamines (r). The so called “bisecting” GlcNAcmay
be attached to the β-linked Man of the trimannosyl core by GnT III in the median Golgi
(9) □-GlcNAc -Mannose -Galactose -Fucose.glycans like hybrid- and high mannose oligosaccharides are more
abundant in CDA II membrane proteins [15,16] but there is no
predominant N-glycan indicating a speciﬁc enzyme deﬁciency in the
synthesis of the glycan. MALDI-TOF analysis of N-glycans derived from
normal band 3 revealed a broad spectrum of small, medium and large
polylactosamine type structures [17]. In contrast to normal band 3, the
largest N-glycans released from CDA II band 3 were truncated and
predominantly contained only one or two lactosamine repeats. In
summary, the typical alteration of N-glycans derived from CDA II
erythrocytes is a truncation of the glycans and the increase of
immature high mannose and hybrid glycans. Further analysis using
antibodies to linear polylactosamines (i-antibodies) and ESI-MS
analysis clearly demonstrated, that polylactosamines on band 3 are
not only truncated but also altered since branching of polylactosa-
mines causing the I-phenotype of erythrocytes is missing in CDA II
erythrocytes [18,19].Whether the lack of polylactosamine branching is
a primary phenomenon of CDA II erythroblasts or due to the general
shortening of N-glycans remains unclear.
Zdebska et al determined the molar composition of erythrocyte
glycoconjugates in various CDA II patients and heterozygous gene
carriers. Total carbohydrates on CDA II band 3 were reduced to about
half of the carbohydrate content of healthy controls [20,21]. Obligatory
heterozygous gene carriers showed an intermediate content of N-
glycans [21]. Polyglycosylceramides in normal red cells carry poly-
lactosaminoglycans similar to those on band 3 attached to ceramide
instead of N-glycans. The amount of glycosphingolipids, lactotriao-
sylceramides, neolactotriaosylceramide and polyglycosylceramides is
increased in CDA II erythrocytes [22]. This could be caused by the
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erythroid cells inwhich glycolipids are preferentially synthesized [23].
There are inconsistent data about the glycosylation of ceramides on
erythrocytes. Zdebska et al demonstrated that ceramides are
hypoglycosylated in CDA II red cells whereas the total amount of
polyglycosylceramides is increased [22]. However, Fukuda et al
described that polylactosaminylceramides are increased in CDA II
red cells [24].
PNGaseF digestion of CDA II erythrocyte membrane proteins,
exclusively cleaving N-linked oligosaccharides, resulted in a band 3
with an apparent molecular weight identical to healthy controls
indicating a defect predominantly affecting the N-glycosylation in
erythroblasts [17].
There is one report that not only erythrocyte membrane proteins
but also serum transferrin, that is synthesized in the liver is
hypoglycosylated in CDA II [25]. Due to the presence of high mannose
and hybrid glycans on transferrin the authors suggested a common
cause for hypoglycosylation of transferrin and erythrocytes in CDA II.
We performed analysis of transferrin in 10 CDA II patients using
isoelectric focusing and could not detect hypoglycosylation (data not
shown).
Due to the frequency of iron overload in CDA II patients, mild
hypoglycosylation of transferrin in the cohort investigated by Fukuda
et al may be secondary to impaired liver function and not a feature of
the disorder.
Investigation of glycophorin A, an erythrocyte membrane protein
that carries 12 O-glycans and one N-glycan, demonstrated a
hypoglycosylation of the protein in CDA II with respect to N- and O-
glycosylation.
In summary, investigation of glycosylation in CDA II erythrocytes
indicates that the defect impairs mainly N-glycosylation but may also
affect glycosylation of ceramides and O-glycosylation of proteins [26].
4.2. “Double membranes” in CDA II erythrocytes
The phenomenon of double membranes in late erythroblasts and
some erythrocytes from CDA II patients was ﬁrst described in 1972
[27]. The origin of the membrane structure close to the erythrocyte
membrane was suggested to be endoplasmic reticulum [28–30]. In
1996, Alloisio et al. proved the inner membrane fragments to be
endoplasmic reticulum using western blot and electron microscopic
studies [31].
The elimination of organelles is a unique feature of erythroid cell
maturation. Late in erythropoiesis the erythroblast loses its nucleus
and becomes a reticulocyte which further degrades internal orga-
nelles in order to become a mature erythrocyte [32]. In addition to the
nuclear abnormalities unique to CDA II erythroblasts, the retention of
organelle residues suggests that CDA II might be amaturation disorder
of erythroblasts indicating that the hypoglycosylation of membrane
proteins could be a secondary phenomenon.
4.3. Enzyme activity studies in CDA II
The consistent truncation of N-glycans on band 3 of erythrocyte
membranes in CDA II led to the assumption that CDA II is primarily a
disorder of glycosylation.
In the past, three different biochemical defects in the N-glycosyla-
tion pathway were proposed to cause CDA II on the basis of enzyme
activity data, western or southern blots, or expression studies: i) a
defect of α-mannosidase II [33] ii) a defect of N-acetylglucosaminyl-
transferase II [24] and iii) a defect of a membrane-bound galactosyl-
transferase [34].
In one patient, enzyme activities of GlcNAcT I, GlcNAcT II, GalT,
GlcNAcT VIII and α-mannosidase II were determined in peripheral
mononucleated cells and cultured B lymphocytes. [33]. While the
enzyme activities of GlcNAcT I, GlcNAcT II, GalT and GlcNAcT VIII werecomparable to healthy controls, the activity of α-mannosidase II was
reduced and expression of αMan II assayed by northern blot analysis
was reduced to b10% of controls. The hypothesis that αMan II plays a
role in the pathogenesis of CDA II was supported by mice defective in
α-mannosidase II that develop dyserythropoiesis and anemia. In these
mice, an alternate pathway using α-mannosidase III compensates for
the defect in non-erythroid mouse cell types [35].
In 2 patients with clinical and biochemical signs of CDA II, the
activity of GlcNAcT II was assayed using lymphocytes. The activity of
GlcNAcT II was reduced to 10% in one patient and to 30% of the activity
of healthy controls in the second CDA II patient [24].
In another patient characterized by a lack of polylactosamines on
erythrocyte proteins and membrane bound ceramides, Fukuda et al
found the activity of a membrane-bound galactosyltransferase
reduced to 24% in monoculeated cells compared to controls. The
overall galactosyltransferase activity in the serum of the patient was
increased and the authors proposed a defect of a membrane-bound
form of a galactosyltransferase as the cause of CDA II in this patient
[34].
Although the enzymatic data were promising to explain the
hypoglycosylation in CDA II molecular analysis of the respective genes
revealed no mutations, neither in the case with low α-mannosidase II
activity and decreased α-mannosidase II mRNA [33], nor in the case
with aberrant splicing of the α-mannosidase II gene [36], nor in the
case with low activity of the membrane bound galactosyltransferase
(M. Fukuda, personal communication).
The major pitfall of all these enzyme activity studies is that–due to
limited availability of erythroblasts–they were performed on cells not
primarily affected by CDA II. In addition, the studied enzymes are of
general importance for the N-glycan synthesis in several tissues and
not speciﬁc to erythropoeisis. Therefore it was not surprising that a
genetic defect of the gene encoding N-acetylglucosaminyltransferase
II, one of the candidates proposed for CDA II, was assigned to a different
disease, congenital disorder of glycosylation type IIa (CDG-IIa), a
severe multisystemic disorder that is clearly not related to CDA II [37].
4.4. Genetic issues in CDA II
Several glycosyltransferases contribute to the assembly of normal
band 3 derived polylactosamines (Fig. 2). Based on the structural data
of erythrocyte membrane derived oligosaccharides of CDA II patients,
early Golgi processing steps have been in the focus of interest but no
defect in the coding genes could be elucidated [38]. The interaction
between glycosyltransferases is complex and to a great extent
unknown. This fact encouraged us to investigate additional glycosyl-
transferases either known to inﬂuence polylactosamine synthesis in
cellular models [39,40] or known to be directly involved in the
assembly of polylactosamines (Fig. 2).
The coding sequences of i-N-acetylglucosaminyltransferase (i-GnT,
B3GNT6, NM_006876), N-acetylglucosaminyltransferase V (GnTV,
MGAT5, NM_002410), galactosyltransferase V (GalTV, B4GALT5,
NM_004776) and fucosyltransferase VIII (FuT8, FUT8, NM_178155)
of a typical CDA II patient were sequenced using cDNA derived from
lymphocyte-RNA as a template. No mutation was found in the coding
sequence of i-GnT transferring N-acetylglucosamine (GlcNAc) in β1,3-
linkage to galactose, essential for polylactosamine synthesis [41],
FuT8, the only known enzyme transferring fucose to the ﬁrst GlcNAc
attached to an asparagine of the protein [42], GalTV, a β1,4-
galactosyltransfersase expressed in bone marrow [43], and GnTV,
transferring GlcNAc in β1,6 linkage to theα1,6-branch of the mannose
core and playing a crucial role in the regulation of polylactosamine
synthesis in some cell culture models [39].
A defect in I-N-acetylglucosaminyltransferase (GCNT2), responsi-
ble for the branching of polylactosamines and the creation of the I-
antigen, was recently found to be the cause of the adult i-phenotype,
an inherited disease clearly different from CDA II [44].
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reveal a candidate gene, in 1997 Gasparini et al. performed a genome
wide linkage analysis of twelve Italian families and one French family
suffering from CDA II with the typical clinical and biochemical picture
of the disorder. A candidate region was elucidated on chromosome
20q11.2, termed CDAN2 locus spanning 5 cM [45]. No gene known to
be involved in glycosylation is located within this area. Sequencing of
candidate genes within this area performed by the same group did not
show any mutation [46].
Later on, families of Italian and other origin were investigated and
did not show association to 20q11.2 [20,47,48] and a founder effect
was discussed [49]. At least 10% of CDA II patients do not show linkage
to the mapping area and the authors suggest that CDA II would be a
heterogeneous disorder [9].
Since then, the location of themarkers on chromosome 20 found to
have the highest LOD score in CDA II were changed and corrected in
the current contigs (build 36.3) indicating that the CDAN2 locusmight
be on Chromosome 20 but is presumably different from the locus
proposed in 1997; a fact that might also explain the exclusion of the
locus in some typical CDA II patients [45] (Fig. 3).
In 2003, Paw et al described dyserythropoiesis in zebraﬁsh as a
sequel of mutations in the gene slc4a1, the band 3 analogon in
zebraﬁsh [50]. The ﬁsh shows anemia and double membranes of some
erythrocytes comparable to CDA II patients. It remains questionable if
zebraﬁsh are good models for red blood cell disorders since–unlike
mature mammalian erythrocytes–ﬁsh erythrocytes remain nucleated.
However, the ﬁsh model implicates, that mutations in band 3 or
binding partners of band 3 might cause dyserythropoiesis. Although
mutations in the gene coding for band 3 are known to cause severe
spherocytosis with distal tubular acidosis [51] speciﬁc mutations
might change the phenotype. Thus Perrota et al performed a
haplotype analysis of the gene locus coding for band 3 (17q21–q22)
and analysis of band 3 protein on SDS-PAGE to address the question
whether band 3 alterationsmay cause CDA II in patients not associated
with the 20q11.2 locus, but did not ﬁnd a genetic linkage nor
abnormalities of the band 3 protein [48].
4.5. Diagnostics of CDA II
The diagnosis of CDA II is typically derived from a bone marrow
cytology showing the characteristic changes of erythroblasts
described above. Due to the early description of increased hemolysis
of CDA II erythrocytes under acidiﬁed conditions and after the
addition of selected donor sera (acidiﬁed serum test, resulting in the
synonymous term HEMPAS, hereditary erythroblastic multinuclearity
with acidiﬁed serum test [52]), hemolysis induced by establishedFig. 3. Localization of deCODE markers in the mapping area of CDAN2 at the time of mappi
highest LOD-scores.donor sera is used to verify the diagnosis in specialized laboratories.
Approximately 30% of randomized donor sera are able to lyse CDA II
erythrocytes under acidiﬁed conditions but never the patients' own
sera [52]. However, the test has a great variability in different
laboratories and the sensitivity as well as speciﬁcity of the test is
rather poor.
Some laboratories use antibodies for the i-antigen in order to prove
the diagnosis of CDA II. While the presence of i-antigen consisting of
linear polylactosamines is physiologic in healthy newborns, it is
subsequently altered to branched polylactosamines coding for the I-
antigen resulting in an adult I-antigen status after 18 month of life
[53,54]. It is well established, that there is an increased amount of i-
antigen on erythrocytes of CDA II patients, resulting in an increased
aggregation after addition of anti-i-antibodies. Sensitivity seems to be
good in a series of 45 CDA II patients [6]. The main pitfall may be that
increased presentation of the i-antigen is also present in other
disorders going along with increased erythrocyte turnover that might
be a differential diagnosis to CDA II [55]. In addition, it has to be
considered that another rare inherited disorder, the so called adult i-
phenotype with persistence of the i-antigen is known, caused by a
defect in a speciﬁc glycosyltransferase [44].
An apparent doubling of the cell membrane of some erythrocytes
of CDA II patients was found as a typical feature in CDA II. As
mentioned above, the doubling is due to residual membranes of
endoplasmic reticulum that normally is eliminated during erythro-
poiesis [31]. Thus, electron microscopy studies of CDA II erythrocytes
might be helpful for the diagnosis of CDA II. However, sensitivity and
speciﬁcity of this phenomenon are unknown, especially with respect
to other disorders affecting erythropoiesis.
Another test for CDA II is based on the detection of endoplasmic
reticulum proteins in membrane preparations of erythrocytes using
SDS-PAGE. Alloisio et al. used calreticulin antibodies to detect this ER
speciﬁc protein in erythrocytes, demonstrating the presence in each of
20 CDA II patients but not in healthy controls, other types of anemia
and obligatory heterozygous gene carriers suggesting that western
blot analysis of calreticulin or other ER-markers from erythrocyte
ghosts is a good and reliable diagnostic marker for CDA II [31].
Already in the ﬁrst years after the ﬁrst description of CDA II as a
distinct entity, an altered mobility of band 3 (anion exchange
protein 1) and band 4.5 (glucose transporter 1) on SDS-PAGE was
described [12]. This increased mobility of band 3 as well as the
decreased band width on SDS-PAGE is used as a diagnostic criterion.
This criterion is a reliable, indirect hint for decreased glycosylation
of band 3 although the appraisal is subjective and sometimes
ambiguous, so that a positive result alone is not sufﬁcient for the
diagnosis.ng (above) and according to the present contig (below). White boxed markers showed
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lentum) speciﬁc to branched polylactosamines were shown to be of
good diagnostic value in CDA II. Due to the severe truncation of
polylactosamines in CDA II erythrocytes, tomato-lectin does not bind
to erythrocyte membranes after separation by SDS-PAGE and
western blotting [17,19]. Using this technique, we did not ﬁnd false
positive or false negative results in our series of 30 patients. The test
cannot be used for newborns and children under 12 months of age,
since tomato-lectin does not bind to erythrocyte membranes in
these patients due to incomplete expression of the i-phenotype
(false positive results). In addition, transfusion of erythrocytes
within 3–4 months before the testing may result in false negative
results.
Modern analytical methods like mass spectrometry were used
to analyse the exact composition and structure of glycans derived
from CDA II erythrocytes and might be suitable for the diagnosis of
CDA II [15,17,22,56]. However, the methods are too elaborate to be
used as a routine diagnostic test and are restricted for scientiﬁc
purposes.
Heimpel et al. proposed that the diagnosis of CDA II requires
evidence of congenital anemia, ineffective erythropoiesis and typical
bone marrow ﬁndings and at least one of the biochemical criteria:
positive acidiﬁed serum test, typical abnormalities in SDS-PAGE of
erythrocyte membranes or double membrane of late erythroblasts
[6]. However, the availability of new, well established biochemical
tests will expand these criteria in the future.
5. Conclusions, history and future perspective
The alteration of N-glycans of erythrocyte membrane proteins
is well established in CDA II. In the late eighties, several
glycosyltransferases were assayed in different CDA II patients and
lower enzyme activities were described in single patients
[24,33,34]. However, genetic analysis did not reveal any mutation
in the genes coding for the proposed enzymes and in other
glycosyltransferases known to contribute to the assembly of the
affected N-glycan attached to band 3 of erythrocyte membranes.
Today, the initial assumption, that CDA II is a primary glycosyla-
tion disorder causing dyserythropoiesis has shifted towards the
view that both, dyserythropoiesis and dysglycosylation, share a
common genetic and pathophysiological origin. Consequently, in
1997 a linkage analysis was done linking the CDA II gene to
chromosome 20q11.2 in the majority of CDA II patients [45].
Surprisingly, in the last 10 years, the CDA II gene was not found in
this area although several genes were sequenced but are obviously
not affected [46].
Thus, 40 years after the classiﬁcation of congenital dyserythro-
poietic anemias and 10 years after the ﬁrst mapping approach for
CDA II, the molecular cause of CDA II remains unknown. The
molecular elucidation of CDA II is considerably aggravated due to
the limited availability of affected erythroblasts. Therefore, it is to
be expected that in contrast to several congenital disorders of
glycosylation where the molecular basis was identiﬁed on the basis
of the structural data of N-glycans [57], the molecular basis of CDA
II will be clariﬁed in the near future using genetic screening tools
or by ﬁnding single patients with informative deletions or crossing
over that allow to pinpoint the chromosomal origin of CDA II.
6. Note added in proof
Most recently, the molecular basis of CDA II has been solved.
Mutations in the secretory coat protein complex II component
SEC23B, affecting the protein transport from the ER to the Golgi, are
causative for CDA II. The gene is located on chromosome 20, but in
accordance with our hypothesis not in the linkage region proposed in
recent years.Acknowledgements
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